BB

BridgeBio Oncology Therapeutics Inc.

BBOT · Nasdaq

BridgeBio Oncology Therapeutics Inc. (BBOT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for BridgeBio Oncology Therapeutics Inc. in 2026. The next earnings report is expected on September 2, 2026.

Scheduled earnings dates

02 Sep 2026 18 Nov 2026

Earnings calendar

Next earnings date

02 Sep 2026

In 14 days

EPS estimate

-0.57

Revenue estimate

0

Past earnings

11 Aug 2026
EPS actual
-0.71 (-24.8%)
estimate -0.57
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.53 (-2.8%)
estimate -0.51
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
05 Mar 2026
EPS actual
-0.49 (+22.6%)
estimate -0.63
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
25 Feb 2026
EPS actual
-0.56 (+11.5%)
estimate -0.63
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

BridgeBio Oncology Therapeutics Inc. missed consensus on EPS, with EPS of $-0.7052 versus an estimate of $-0.565, while revenue met expectations at $0. In the prior quarter EPS also missed expectations and revenue likewise met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Eli Wallace
Employees
62
IPO date
12 Aug 2025
ISIN
US1079241022
Website
bbotx.com

Frequently asked questions

When does BridgeBio Oncology Therapeutics Inc. (BBOT) next report earnings?

BridgeBio Oncology Therapeutics Inc. (BBOT) is scheduled to report earnings on September 2, 2026.

What was BridgeBio Oncology Therapeutics Inc.'s most recent earnings date?

BridgeBio Oncology Therapeutics Inc. (BBOT) last reported earnings on August 11, 2026.

Where is BridgeBio Oncology Therapeutics Inc. stock listed?

BridgeBio Oncology Therapeutics Inc. (BBOT) is listed on Nasdaq.